Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) is a molecular diagnostics company focused on artificial-intelligence-powered epigenetic testing for the early detection and management of cardiovascular disease. The company completed its business combination with special purpose acquisition company Mana Capital Acquisition Corp. in 2022, with Mana Capital LLC serving as sponsor, and began trading on Nasdaq under the CDIO ticker following the close of that transaction. Operating in the healthcare diagnostics sector, the company has remained publicly listed as a post-combination entity since that time. On September 8, 2026, Cardio Diagnostics filed a DEFA14A — additional definitive proxy soliciting materials — with the Securities and Exchange Commission under accession number 0001079973-26-001223. For complete data on CDIO, its SPAC history, and all related filings, sign up for full access at SpacDesk.